Our Front-runner: KZR-616

First-in-Class Selective Immunoproteasome Inhibitor

KZR-616 offers a novel approach to harmonizing the immune system via selective immunoproteasome inhibition. Playing a critical role in the body's immune system, the immunoproteasome is abundantly expressed in immune cells and acts as a master regulator of multiple cellular functions. By selectively inhibiting the immunoproteasome, KZR-616 has the potential to affect multiple drivers of immune-mediated diseases.

Learn more about the science behind immunoproteasome inhibition.

A Pipeline in A Drug

With its broad immunomodulatory capabilities, KZR-616 has broad therapeutic potential and is distinctly different from other drugs available to those living with autoimmune diseases . Active in a number animal models of autoimmune diseases and compelling early clinical data , KZR-616 offers a “pipeline in a drug” with the potential to disrupt the treatment paradigm in a wide array of immune-mediated and autoimmune diseases.  

Clinical Trials

The MISSION Phase 1b trial is evaluating the safety, tolerability and early efficacy signals in patients with lupus with and without nephritis. Data gathered to date support the development of KZR-616 as a chronic therapy for a wide range of severe, chronic autoimmune diseases and immune-mediated disorders. Phase 2 clinical trials are currently underway in lupus nephritis and dermatomyositis/polymyositis.

Find out more about our Clinical Trials with KZR-616

Our Therapeutic Potential Goes the Distance

We are leveraging KZR-616’s broad immuno-modulatory potential to initially study severe, chronic autoimmune diseases – including lupus nephritis and idiopathic inflammatory myopathies such as polymyositis and dermatomyositis.

Lupus Nephritis

Lupus nephritis or, LN, is an inflammation of the kidney that is serious complication of the disease, systemic lupus erythematosus (lupus or SLE). SLE is a chronic, complex and oftentimes disabling autoimmune disorder whereby the body’s own immune system attacks itself. SLE predominantly affects women and is more prevalent in women of color. The Centers for Disease Control and Prevention estimates there are approximately 322,000 people living with SLE in the United States and the Lupus Foundation of America estimates up to 1.5 million people are living with a form of lupus in the U.S.. Approximately half those living with lupus will develop lupus nephritis at some point during their disease. The presence of nephritis dramatically increases mortality risk in lupus patients, and there are currently no FDA-approved therapies for lupus nephritis in the U.S and EU.

Polymyositis/ Dermatomyositis

Dermatomyositis (DM) and polymyositis (PM) are idiopathic inflammatory myopathies, which are serious disorders involving muscle inflammation and weakness. The inflammatory myopathies are disabling autoimmune disorders whereby the body’s own immune system attacks the muscles and cells. There are limited approved treatments for myositis, and according to the Myositis Association, an estimated 70,000 people in the U.S. have these disorders.